drug
ET-800
Marketedupdated 5mo agoby $ETON Eton Pharmaceuticals, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugNEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE16 co-mentions · 6 sources
- tagApproval14 co-mentions · 5 sources
- drugHYDROCORTISONE12 co-mentions · 6 sources
- drugpolymyxin B4 co-mentions · 2 sources
- drugCIPROFLOXACIN HYDROCHLORIDE2 co-mentions · 1 sources
- drugciprofloxacin2 co-mentions · 1 sources
- drugciprofloxacin hydrochloride ER2 co-mentions · 1 sources
- tagSmall Molecule1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 35 approved and 37 investigational indications.
indications
investigational
Multiple SclerosisIBD (Crohn's + UC)Rheumatoid ArthritisPsoriasisLupusAsthma
all catalysts(3)
approval · 3
Sep 30, 2025
approval
$AMRX20.30+1.15%
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE (HYDROCORTISONE) — FDA approval
ET-800
→
Oct 29, 2025
approval
$AMRX20.30+1.15%
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE (HYDROCORTISONE) — FDA approval
ET-800
→
Feb 25, 2026
approval
HYDROCORTISONE — FDA approval
ET-800
→
Trials studying ET-800
- phase1Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone
- phase2Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH
- phase1An Investigational Study of Hydrocortisone
- phase3Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- phase2Lazarus: IT Therapy for ICANS
- phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- phase1A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
- phase1A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 19, 2032
~6.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Feb 23, 2043formulationUS 11904046
- Feb 23, 2043method-of-use (U-4215)US 12133914
- May 12, 2034formulationUS 9649280
- May 12, 2034formulationUS 9649280
- May 12, 2034formulationUS 9649280
- May 12, 2034formulationUS 9649280
- Jan 10, 2033method-of-use (U-3075)US 9675559
- Jan 10, 2033method-of-use (U-3075)US 9675559
- Jan 10, 2033method-of-use (U-3075)US 9675559
- Jan 10, 2033method-of-use (U-3075)US 9675559
- Nov 19, 2032method-of-use (U-3075)US 9717740
- Nov 19, 2032method-of-use (U-3075)US 9717740
- Nov 19, 2032method-of-use (U-3075)US 9717740
- Nov 19, 2032method-of-use (U-3075)US 9717740
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that